相关实验视频

Updated: Jan 11, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

KAT2A:一个预后生物标志物,影响肺腺癌的增殖和免疫逃逸

Zhangmin Ke^1,2, Hao Xu³, Kaikai Shen⁴

¹Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, China.

|November 12, 2025

概括

在肺腺癌 (LUAD) 中,KAT2A的表达很高,与预后不佳和瘤进展相关. 抑制KAT2A抑制了LUAD生长和免疫逃避,表明其作为预后生物标志物和治疗点的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

肺腺癌 (LUAD) 是癌症死亡的主要原因.
KAT2A与瘤发生和瘤进展有关.
在LUAD中KAT2A的特殊作用需要全面调查.

研究的目的:

系统地研究KAT2A在LUAD中的作用.
评估KAT2A的表达,预后意义和LUAD中的功能机制.
探索KAT2A与免疫透的相关性及其治疗潜力.

主要方法:

对KAT2A表达和预测值的TCGA和GEO数据库的分析.
基因本体学 (GO) 和基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因.
在体外 (CCK-8,殖民地形成,流细胞计) 和体内 (异种移植模型) 实验.

主要成果:

在LUAD组织和细胞中,KAT2A的表达显著升高,与晚期TNM和病理阶段相关.
高KAT2A表达与降低整体存活率有关,并被证实为独立的预后因素.
在LUAD模型中,KAT2A敲击抑制了增殖,诱导了亡,抑制了瘤生长,并调节了免疫逃避.

结论:

KAT2A是LUAD的潜在预后生物标志物.
在LUAD进展和免疫逃避中,KAT2A起着至关重要的作用.
向KAT2A可能为LUAD患者提供一种新的治疗策略.

关键词:

免疫逃逸是一种免疫逃避.在KAT2A中,它是KAT2A 肺部腺癌是肺部的癌症.预测预后预测预测

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...